Current status of PET/CT in the diagnosis and follow up of lymphomas

Revista Brasileira de Hematologia e Hemoterapia

Carlos Alberto Buchpiguel¹ 

[1] ,Universidade de São Paulo Faculdade de Medicina Hospital das ClínicasSão Paulo SP ,Brazil

关键词: Lymph Nodes;    Lymphoma;    Positron-emission tomography;    Fluorodeoxyglucose F18;    Lymphoma;    Hodgkin's disease;    Lymphoma;    non-Hodgkin;   

DOI  :  10.5581/1516-8484.20110035

来源: SciELO

【 摘 要 】

Lymphomas are a heterogeneous group of malignancies that have a distinct biological behavior according to the subtype and degree of differentiation. Adequate staging, which has a direct impact on prognosis, is essential to properly plan therapy. Structural cross-sectional imaging, such as computed tomography, has been the standard imaging tool to stage and monitor patients with lymphoma. However, molecular imaging such as positron emission tomography has shown complementary diagnostic and prognostic values. This review discusses the current value of positron emission tomography imaging using 2-[fluorine-18]fluoro-2-deoxy-d-glucose in staging, restaging, monitoring and detecting relapse in Hodgkin's and non-Hodgkin lymphoma.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License